ezCaretech Co. LTD (099750) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of ezCaretech Co. LTD stock KRW 2,781, price KRW 6,000, that is 53.6% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 5,920 KRW – 26,592 KRW · fair‑value band 2,506 KRW – 3,127 KRW · the 6,000 KRW price screens above the 2,781 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow ezCaretech Co. in your weekly email
Every Wednesday you see whether ezCaretech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ezCaretech Co., LTD engages in the provision of various modules for hospital operations in South Korea, Saudi Arabia, the United States, Japan, and internationally.
Show moreShow less
The company's solutions include BESTCare 2.0, an EMR/EHR solution that optimizes workflows, enhances patient safety and empowerment, minimizes workload for healthcare professionals, and ensures data sharing.
It also offers Behavioral specialized HER, a solution for behavioral health; and Cloud HER, which provides a standardized system, security, and software maintenance. The company is headquartered in Seoul, South Korea.
Stock analysis
ezCaretech Co. LTD (099750) currently trades at 6,000 KRW, while our model-based Fair Value estimate is 2,781 KRW, 54% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 8,186 KRW per share, and 7 of the 14 models we run sit above the 6,000 KRW price.
Bear case: the Asset-Based group reads lowest at 1,085 KRW, and 7 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 2,506 KRW (bear) to 3,127 KRW (bull), the price of 6,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
ezCaretech Co. LTD reported revenue of 78.9B KRW in FY2026 versus 92.1B KRW in FY2022, a compound −3.8%/yr. Reported net income was 6.1B KRW in FY2026.
Key figures
Market cap 81.9B KRW (≈ $60.5M) Micro · P/E ratio 11.9 · P/S ratio 0.98 · EPS (TTM) 505.80 KRW · Net margin 8.3% · Return on equity 16.8% · Return on assets (EBIT) −1.5% (5-year average) · Operating margin 1.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −54%, 099750 screens richer than that median.
Fair Value models
Bear2,506 KRWFair Value 2,781 KRWBull3,127 KRW
Price 6,000 KRW · Downside -53.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (309.02 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings1,401 KRW1,746 KRW2,171 KRW75
Residual Income2,947 KRW3,352 KRW4,235 KRW71
EPV2,948 KRW3,272 KRW3,539 KRW70
All 14 models by family
DCF Models
Owner Earnings1,401 KRW1,746 KRW2,171 KRW75
Earnings-Based
Graham-Dodd3,035 KRW7,933 KRW10,350 KRW65
PEG = 1.01,512 KRW2,160 KRW2,808 KRW57
EPV2,948 KRW3,272 KRW3,539 KRW70
Multiples
P/E Multiple7,364 KRW9,818 KRW12,273 KRW63
P/S Multiple5,690 KRW7,587 KRW9,483 KRW58
P/B Multiple11,030 KRW14,707 KRW18,384 KRW55
EV/EBIT5,124 KRW6,686 KRW8,249 KRW63
EV/EBITDA5,269 KRW6,881 KRW8,492 KRW64
EV/Revenue3,781 KRW5,215 KRW6,650 KRW51
Asset-Based
NCAV (Graham)716.28 KRW1,085 KRW1,357 KRW52
Economic Profit
Residual Income2,947 KRW3,352 KRW4,235 KRW71
ROIC Compounder2,948 KRW3,272 KRW3,679 KRW70
Growth Earnings
Growth-Adj P/E5,730 KRW8,186 KRW10,642 KRW67
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+8.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 3 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+57.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+57.6%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−12% → 6%
2026 sits 71% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−53.6% · Below median
Profitability
Return on equity (12 months)16.8% · Top 25%
Return on assets9.5% · Top 25%
Net margin (12 months)8.3% · Above median
Operating margin (12 months)1.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)28.5% · Top 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (12 months)11.9× · Cheapest 25%
P/B1.83× · Cheaper than median
P/S (12 months)0.98× · Cheapest 25%
EV/EBITDA11.6× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 5
FUTURE (revenue growth)100· sector 46
PAST (return on equity)67· sector 10
HEALTH (low debt)0· sector 98
DIVIDEND (yield)0· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ezCaretech Co. LTD (099750) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 2,781 KRW versus a price of 6,000 KRW, about 54% lower (overvalued).
What is the fair value of 099750?
Our model-based fair value for ezCaretech Co. LTD is 2,781 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 6,000 KRW.
What is the quality score of 099750?
ezCaretech Co. LTD has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ezCaretech Co. LTD (099750)?
Our model-based price target is the fair value of 2,781 KRW (as of Nov 9, 2026) from 14 valuation models. Cautious scenario 2,506 KRW, optimistic scenario 3,127 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ezCaretech Co. LTD stock forecast for 2026?
Our models put fair value at 2,781 KRW, about 54% lower versus a price of 6,000 KRW (overvalued). Cautious scenario 2,506 KRW, optimistic scenario 3,127 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ezCaretech Co. LTD (099750)?
ezCaretech Co. LTD reported trailing-twelve-month revenue of about 83.4B KRW (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of ezCaretech Co. LTD (099750)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ezCaretech Co. LTD it is 2,781 KRW per share (as of Nov 9, 2026), against a price of 6,000 KRW. It is the blended result of 14 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is ezCaretech Co. LTD stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 099750 trades above its calculated fair value: price 6,000 KRW, fair value 2,781 KRW, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 099750?
No. The price is what the market pays today (6,000 KRW); the fair value is what the company's own numbers justify (2,781 KRW). For ezCaretech Co. LTD the two are 3,219 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ezCaretech Co. LTD worth?
The market values ezCaretech Co. LTD at about 81.9B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 6,000 KRW; our models calculate a fair value of 2,781 KRW per share.
What do the bullish and bearish scenarios say about 099750?
Our models span a range for ezCaretech Co. LTD: cautious scenario 2,506 KRW, base 2,781 KRW, optimistic 3,127 KRW per share (as of Nov 9, 2026, price 6,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 099750?
ezCaretech Co. LTD trades at a price-to-earnings ratio of 11.9 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2,781 KRW is built from several models across several years. Other multiples: P/B 1.8, P/S 1.0, EV/EBITDA 11.6.
How solid is the balance sheet of ezCaretech Co. LTD (099750)?
Balance-sheet figures for ezCaretech Co. LTD (as of Nov 9, 2026): return on equity 16.8%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 099750 from its 52-week high?
ezCaretech Co. LTD trades at 6,000 KRW, about 48% below its 52-week high of 11,450 KRW and 1% above the low of 5,920 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2,781 KRW is for.
Which stocks are comparable to ezCaretech Co. LTD?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ezCaretech Co. LTD stock attractive at the current price?
The data as of Nov 9, 2026: price 6,000 KRW, calculated fair value 2,781 KRW (−54%), Quality Score 48/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 099750 calculated?
We run ezCaretech Co. LTD through 14 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2,781 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. ezCaretech Co. LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ezCaretech Co. LTD (099750)?
The closing price on Nov 6, 2026 was 6,000 KRW. Our model-based fair value is 2,781 KRW, about 54% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ezCaretech Co. LTD right now?
The price sits above even our optimistic bull case (3,127 KRW). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of ezCaretech Co. LTD
How large is the market capitalisation of ezCaretech Co. LTD (099750)?
The market capitalisation of ezCaretech Co. LTD is 81.9B KRW (≈ $60.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ezCaretech Co. LTD (099750)?
The price-to-sales ratio of ezCaretech Co. LTD is 0.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ezCaretech Co. LTD (099750)?
Earnings per share at ezCaretech Co. LTD are 505.80 KRW (price ÷ EPS = P/E 11.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ezCaretech Co. LTD (099750)?
The net margin of ezCaretech Co. LTD is 8.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ezCaretech Co. LTD (099750)?
The return on equity (ROE) of ezCaretech Co. LTD is 16.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ezCaretech Co. LTD (099750)?
On an EBIT basis the return on assets of ezCaretech Co. LTD is −1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ezCaretech Co. LTD (099750)?
The operating margin of ezCaretech Co. LTD is 1.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ezCaretech Co. LTD (099750)?
Revenue at ezCaretech Co. LTD is growing +28.5% versus a year earlier (3y avg +2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ezCaretech Co. LTD (099750)?
Earnings per share at ezCaretech Co. LTD are growing +4.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ezCaretech Co. LTD (099750) generate?
The free cash flow of ezCaretech Co. LTD is −3.5B KRW (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch ezCaretech Co. LTD in the live analysis
One click puts ezCaretech Co. LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026